Foresee presented its first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2 pulmonary hypertension associated with interstitial lung disease (PH-ILD) clinical study (WINDWARD study) currently in planning, at the American Heart Association (AHA) 2023 Annual Meeting.

Oral Presentation Title：A New Therapeutic Paradigm for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Windward Phase 2 Study

Date: Saturday, November 11, 2023

Time: 11:15 - 11:45 Eastern

Location: Pennsylvania Convention Center, Heart Theater‚ Science and Technology Hall‚ Level 2, HT.01

The presentation slide deck is available as follows: 

AHA presentation slide deck